Vimarsana
Biggest News Aggregation in the World

Page 2 - Pediatric Eoe News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pediatric Eoe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pediatric Eoe Today - Breaking & Trending Today

Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) -January 25, 2024 at 02:31 pm EST - Vimarsana News

Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) -January 25, 2024 at 02:31 pm EST

Published: January 25, 2024

Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis  Approval based on Phase 3 EoE KIDS trial showing a greater...

Source: marketscreener.com
Related Topics:
France GeneralEvan BerlandIlana YellenNaimish PatelCorentine DriancourtEva Schaefer JansenVesna TosicTarik ElgoutniGeorged YancopoulosSally BainNathalie PhamFelix LauscherHead Of Global DevelopmentDrug AdministrationRegeneron Genetics CenterDupilumab Development ProgramExchange CommissionRegeneron Pharmaceuticals IncPriority ReviewGlobal DevelopmentPediatric EoeSymptom Questionnaire CaregiverChief Scientific OfficerDupixent Pediatric Eosinophilic EsophagitisPrivate Securities Litigation Reform Act
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) - Vimarsana News

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

Published: January 25, 2024

Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for...

Source: marketscreener.com
Related Topics:
France GeneralSally BainRegeneron VelocimmuneTarik ElgoutniFelix LauscherArnaud DelepineVesna TosicNaimish PatelIlana YellenGeorged YancopoulosEva Schaefer JansenNathalie PhamEvan BerlandCorentine DriancourtRegeneron Velocimmune TechnologyExchange CommissionRegeneron Genetics CenterRegeneron Pharmaceuticals IncDupilumab Development ProgramGlobal DevelopmentDrug AdministrationGlobenewswire IncPriority ReviewChief Scientific OfficerPediatric Eoe